Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Jaktinib for Myelofibrosis
Recruiting1 awardPhase 1
Canton, Ohio
This trial is testing Jaktinib, a drug for treating Myelofibrosis in patients who haven't responded to other treatments. The drug aims to block signals that help cancer cells grow. Jaktinib is currently being studied for its potential to treat myelofibrosis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service